The identification of 7-[(R)-2-((1S,2S)-2-benzyloxycyclopentylamino)-1-hydroxyethyl]-4-hydroxybenzothiazolone as an inhaled long-acting ß2-adrenoceptor agonist.
Bioorg Med Chem Lett
; 24(17): 4341-7, 2014 Sep 01.
Article
en En
| MEDLINE
| ID: mdl-25065493
ABSTRACT
The optimisation of two series of 4-hydroxybenzothiazolone derived ß2-adrenoceptor agonists, bearing α-substituted cyclopentyl and ß-phenethyl amino-substituents, as inhaled long-acting bronchodilators is described. Analogues were selected for synthesis using a lipophilicity based hypothesis to achieve the targeted rapid onset of action in combination with a long duration of action. The profiling of the two series led to identification of the α-substituted cyclopentyl analogue 2 as the optimal compound with a comparable profile to the inhaled once-daily long-acting ß2-adrenoceptor agonist indacaterol. On the basis of these data 2 was promoted as the backup development candidate to indacaterol from the Novartis LABA project.
Palabras clave
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
Receptores Adrenérgicos beta 2
/
Benzotiazoles
/
Agonistas de Receptores Adrenérgicos beta 2
Tipo de estudio:
Diagnostic_studies
Límite:
Animals
Idioma:
En
Año:
2014
Tipo del documento:
Article